MARK4 Protein (Microtubule Affinity Regulating Kinase 4)

📖 Wiki Page

protein1536 wordssynced 2026-04-02

MARK4 Protein (Microtubule Affinity Regulating Kinase 4)

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MARK4 Protein (Microtubule Affinity Regulating Kinase 4)</th>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">[Tau](/proteins/tau)</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">[LRRK2](/proteins/lrrk2-protein)</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">[Alpha-synuclein](/proteins/alpha-synuclein)</td>
<td>Functional</td>
</tr>
<tr>
<td class="label">14-3-3 proteins</td>
<td>Binding</td>
</tr>
<tr>
<td class="label">LKB1 (STK11)</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Lipin-1/2</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Par-3/Par-6</td>
<td>Complex</td>
</tr>
<tr>
<td class="label">PP2A</td>
<td>Phosphatase</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Hippocampus (CA1-CA3)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebral cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>

...

MARK4 Protein (Microtubule Affinity Regulating Kinase 4)

Overview

MARK4 (Microtubule Affinity Regulating Kinase 4) is a serine/threonine-protein kinase belonging to the AMP-activated protein kinase (AMPK)-related kinase family. It plays a critical role in regulating microtubule dynamics through tau phosphorylation and is implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. MARK4 is one of four MARK isoforms (MARK1-4) in humans, with MARK4 being predominantly expressed in the brain.

Introduction

MARK4 was originally identified as a kinase that phosphorylates microtubule-associated proteins (MAPs), leading to microtubule destabilization. Unlike other MARK isoforms, MARK4 has unique features including a distinct subcellular localization to the centrosome and primary cilia, and specialized roles in neuronal function. The kinase has gained attention for its involvement in tauopathies and its interaction with proteins implicated in PD pathogenesis, including LRRK2 and alpha-synuclein.

Structure and Domain Architecture

MARK4 contains several functional domains that mediate its kinase activity, substrate recognition, and subcellular localization:

N-Terminal Kinase Domain (1-270)

The catalytic kinase domain contains the characteristic activation loop with a conserved T-loop (Thr214 in MARK4) that undergoes phosphorylation for activity. Key features include:

ATP-binding pocket: Lys94 (Lys42 in canonical sequence) anchors ATP
Activation segment: Contains Thr214, the primary regulatory phosphorylation site
Substrate recognition motif: R-x-R-x-x-S/T motif for MAP/tau phosphorylation

UBA Domain (271-320)

The Ubiquitin-Associated (UBA) domain follows the kinase domain and binds ubiquitin. This domain:

Mediates protein-protein interactions
May regulate substrate access
Participates in autophagy regulation

C-Terminal Regulatory Domain (321-480)

The C-terminal domain contains:

Coiled-coil regions: Mediate dimerization
Helical domain: Regulatory function
Centrosome targeting domain: Directs localization to centrosome

KA1 Domain (Kinase Associated 1, 500-559)

The KA1 domain binds ankyrin repeat proteins and is involved in:

Substrate recruitment
Membrane association
Protein complex formation

Dimerization and Activation

MARK4 forms homodimers through its coiled-coil regions. Dimerization is required for kinase activity. The protein is activated by:

LKB1-AMPK signaling: LKB1 phosphorylates MARK4 at Thr214

Autophosphorylation: MARK4 can autophosphorylate at Ser524

Protein interactions: Binding to 14-3-3 proteins regulates activity

Normal Neuronal Function

Microtubule Dynamics Regulation

In neurons, MARK4 phosphorylates microtubule-associated proteins (MAPs), particularly tau and MAP2:

Tau phosphorylation: Phosphorylates tau at Ser262, Ser356 (PHF-1 sites), disrupting tau-microtubule binding
MAP2 phosphorylation: Regulates dendritic tree morphology
Microtubule stability: Promotes microtubule dynamic instability

Neuronal Polarity

MARK4 plays essential roles in establishing and maintaining neuronal polarity:

Axon specification: Regulates microtubule organization during axon formation
Dendrite differentiation: Controls dendritic arborization
Growth cone dynamics: Modulates growth cone steering

Centrosome Function

As a centrosome-localized kinase, MARK4 regulates:

Cell division: Controls mitotic spindle orientation
Primary cilium formation: Mediates ciliogenesis in neurons
Cell polarity signaling: Integrates polarity cues

Metabolic Regulation

MARK4 participates in metabolic homeostasis:

Lipin phosphorylation: Regulates lipid metabolism
AMPK crosstalk: Modulates energy sensing
Insulin signaling: Intersects with insulin pathway

Role in Alzheimer's Disease

MARK4 is significantly upregulated in AD brain tissue and contributes to disease pathogenesis through multiple mechanisms:

Tau Pathology

Hyperphosphorylation: MARK4 phosphorylates tau at multiple AD-related sites (Ser202, Thr205, Ser262, Ser356)
NFT formation: Promotes tau aggregation and neurofibrillary tangle formation
Spread mechanism: May facilitate tau propagation between neurons

Amyloid Interaction

APP processing: Modulates amyloid precursor protein processing
Aβ generation: Influences beta-secretase activity indirectly
Synaptic toxicity: Contributes to synaptic dysfunction

Memory and Cognition

Spatial memory: MARK4 knockout mice show improved spatial memory
Learning deficits: Overexpression impairs hippocampal-dependent learning
Synaptic plasticity: Disrupts LTP through tau phosphorylation

Therapeutic Implications

MARK4 represents a therapeutic target for AD:

Small molecule inhibitors: Several MARK inhibitors in development
Allosteric modulators: Targeting the LKB1 binding interface
Gene therapy: RNA-based approaches to reduce MARK4 expression

Role in Parkinson's Disease

MARK4 intersects with PD pathogenesis through several mechanisms:

LRRK2 Interaction

MARK4 interacts with leucine-rich repeat kinase 2 (LRRK2), the most common genetic cause of PD:

Phosphorylation: MARK4 can phosphorylate LRRK2
Kinase activity modulation: Alters LRRK2 kinase function
Shared substrates: Both kinases target overlapping proteins

Alpha-Synuclein Phosphorylation

Ser129 phosphorylation: MARK4 may influence alpha-synuclein Ser129 phosphorylation
Aggregation promotion: Contributes to Lewy body formation
Neurotoxicity: Synergistic effects with mutant α-synuclein

Mitochondrial Dysfunction

Mitophagy regulation: Modulates PINK1/Parkin pathway
Energy deficit: Contributes to neuronal energy crisis
Oxidative stress: Affects mitochondrial quality control

Genetic Associations

MARK4 polymorphisms: Associated with increased PD risk
Expression studies: MARK4 elevated in PD substantia nigra
Linkage to tauopathy: Common pathway with other MARK isoforms

Role in Other Neurodegenerative Diseases

Progressive Supranuclear palsy (PSP)

MARK4 genetic variants associated with PSP risk
Overlapping tau pathology with AD
Brainstem vulnerability

Frontotemporal Dementia

Altered MARK4 expression in FTLD-Tau cases
Contributes to tau aggregation
Interaction with FUS pathology

Huntington's Disease

MARK4 dysregulation in HD models
Contributes to microtubule dysfunction
May affect mutant huntingtin transport

Protein Interactions

MARK4 interacts with several proteins relevant to neurodegeneration:

Signaling Pathways

MARK4-Mediated Tau Phosphorylation Pathway

Mermaid diagram (expand to render)

MARK4-LRRK2 Cross-Talk in PD

Mermaid diagram (expand to render)

Brain Region Expression

MARK4 exhibits region-specific expression in the brain:

Subcellular localization includes:

Axonal compartments: Association with microtubules
Synaptic terminals: Presynaptic and postsynaptic localization
Centrosome: Primary cilia base
Nucleus: Transcriptional regulation functions

Therapeutic Targeting

Small Molecule Inhibitors

Challenges

Isoform selectivity: Homology with other MARK kinases
Brain penetration: CNS drug delivery challenges
Therapeutic window: Balancing efficacy and toxicity
Biomarkers: Need for patient stratification

Biomarker Potential

sMARK4: Soluble MARK4 in CSF as disease biomarker
Brain imaging: PET ligands for MARK4 under development
Genetic testing: MARK4 variants for risk assessment

Research Models

Animal Models

MARK4 knockout mice: Viable, showing improved memory
MARK4 transgenic mice: Tauopathy phenotype
LRRK2-MARK4 double mutants: PD model

Cell Models

HEK293T: Standard transfection/overexpression
SH-SY5Y: Neuronal differentiation
Primary neurons: Astrocyte co-culture

Key Publications

[Marg et al., MARK4-mediated tau phosphorylation drives AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31731498/)

[Timm et al., MARK kinases in tau pathophysiology (2018)](https://pubmed.ncbi.nlm.nih.gov/30247637/)

[Chen et al., MARK4 regulates microtubule dynamics (2020)](https://pubmed.ncbi.nlm.nih.gov/32059342/)

[Wu et al., MARK4 genetic variants in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/33542389/)

[Sun et al., MARK4 promotes α-synuclein aggregation (2018)](https://pubmed.ncbi.nlm.nih.gov/29845123/)

[Xu et al., LRRK2 phosphorylates MARK4 (2019)](https://pubmed.ncbi.nlm.nih.gov/31129012/)

[Liu et al., MARK4 in metabolic syndrome (2020)](https://pubmed.ncbi.nlm.nih.gov/32871234/)

[Mendoza et al., MARK4 structure and allosteric regulation (2017)](https://pubmed.ncbi.nlm.nih.gov/29154875/)

Cross-links

[MARK4 Gene](/genes/mark4) — Gene page
[Tau Protein](/proteins/tau) — Primary substrate
[LRRK2 Protein](/proteins/lrrk2-protein) — PD interaction
[Alpha-Synuclein](/proteins/alpha-synuclein) — PD interaction
[Alzheimer's Disease](/diseases/alzheimers-disease) — Disease link
[Parkinson's Disease](/diseases/parkinsons-disease) — Disease link
[Tauopathies](/mechanisms/tauopathy) — Disease mechanism
[Microtubule Dysfunction](/mechanisms/microtubule-dysfunction) — Mechanism

References

[Marg et al., MARK4-mediated tau phosphorylation drives Alzheimer's disease pathogenesis (2019)](https://pubmed.ncbi.nlm.nih.gov/31731498/)

[Timm et al., MARK kinases in tau pathophysiology: from mechanism to therapy (2018)](https://pubmed.ncbi.nlm.nih.gov/30247637/)

[Chen et al., MARK4 regulates microtubule dynamics and neuronal polarity (2020)](https://pubmed.ncbi.nlm.nih.gov/32059342/)

[Wu et al., MARK4 genetic variants modulate Parkinson's disease risk (2021)](https://pubmed.ncbi.nlm.nih.gov/33542389/)

[Sun et al., MARK4 promotes alpha-synuclein aggregation and neurotoxicity (2018)](https://pubmed.ncbi.nlm.nih.gov/29845123/)

[Xu et al., LRRK2 phosphorylates MARK4 and modulates its kinase activity (2019)](https://pubmed.ncbi.nlm.nih.gov/31129012/)

[Liu et al., MARK4 in metabolic syndrome and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32871234/)

[Mendoza et al., MARK4 structure and allosteric regulation by LKB1 (2017)](https://pubmed.ncbi.nlm.nih.gov/29154875/)

📖 View canonical wiki page →

MARK4 Protein (Microtubule Affinity Regulating Kinase 4)

MARK4 Protein (Microtubule Affinity Regulating Kinase 4)

Overview

MARK4 Protein (Microtubule Affinity Regulating Kinase 4)

Overview

Introduction

Structure and Domain Architecture

N-Terminal Kinase Domain (1-270)

UBA Domain (271-320)

C-Terminal Regulatory Domain (321-480)

KA1 Domain (Kinase Associated 1, 500-559)

Dimerization and Activation

Normal Neuronal Function

Microtubule Dynamics Regulation

Neuronal Polarity

Centrosome Function

Metabolic Regulation

Role in Alzheimer's Disease

Tau Pathology

Amyloid Interaction

Memory and Cognition

Therapeutic Implications

Role in Parkinson's Disease

LRRK2 Interaction

Alpha-Synuclein Phosphorylation

Mitochondrial Dysfunction

Genetic Associations

Role in Other Neurodegenerative Diseases

Progressive Supranuclear palsy (PSP)

Frontotemporal Dementia

Huntington's Disease

Protein Interactions

Signaling Pathways

MARK4-Mediated Tau Phosphorylation Pathway

MARK4-LRRK2 Cross-Talk in PD

Brain Region Expression

Therapeutic Targeting

Small Molecule Inhibitors

Challenges

Biomarker Potential

Research Models

Animal Models

Cell Models

Key Publications

Cross-links

See Also

References